The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/111709
Shin Nippon Biomedical Laboratory, Ltd. ��� Kagoshima, Japan www.snbl.com ��� (425) 322-2456 key locations: Baltimore, MD; Boston, MA; and Everett, WA; United States; Kagoshima, Osaka, Tokyo, and Wakayma, Japan; Cambodia contact: Ralph Lin, Ph.D., global strategy & corporate development officer, president, TR-USA rlin@snblusa.com Drug Life Cycle Stages: Research & Development ��� Discovery, Preclinical, Clinical (Phase 1, Phase 2, and Phase 3) Main Service Areas: Bioanalytical, Clinical, Preclinical SERVICES & CAPABILITIES: As a global CRO, SNBL provides a full range of integrated non-clinical and clinical services (PhI-IV) with facilities in the U.S., Japan, and Asia. In the U.S., SNBL offers GLP preclinical services, Ph1/2 clinical services, and animal colony management. THERAPEUTIC AREAS: All major therapeutics areas including: cardiovascular, infectious disease, oncology, endocrinology, respiratory disease, kidney disease, GI, diagnostics, sensory organs, CNS, metabolic disease, and urogenital disease. ���This year Shin Nippon Biomedical Laboratories, Ltd (SNBL) enters its 56th year of existence since its founding as the first pharmaceutical contract research organization (CRO) in Japan. Since then, we have grown into a global company supporting pharmaceutical companies with a full range of integrated drug development services. SNBL prides itself in delivering high quality data with the exceptional precision needed to rapidly advance new medical therapies and innovations that improve patients��� lives.��� ��� Ryoichi Nagata, M.D., Ph.D.,FFPM, president and CEO Toxikon Corporation ��� Bradford, MA www.toxikon.com ��� (781) 275-3330 key locations: Toxikon Europe N.V.; Leuven, Belgium contact: Jacqueline Wong ��� Jacqueline.wong@toxikon.com Drug Life Cycle Stages: Research & Development ��� Preclinical Main Service Areas: Bioanalytical, Preclinical SERVICES & CAPABILITIES: In vivo and in vitro studies, efficacy and surgical research, ocular drug development synthesis and formulation, biocompatibility, full IND/NDA studies, analytical and bioanalytical, extractables and leachable, histology/pathology, PK/TK/ADME/DMPK, acute/subchronic/chronic genetic/reproductive toxicology, animal models THERAPEUTIC AREAS: Including, but not limited to, cancer, neurodegenerative diseases, ocular (uveitis, glaucoma, dry eye, corneal, choroidial and retinal NV), IBD, dermatitis, obesity, and wound healing KEY INDUSTRY PARTNERS: Biotech, pharmaceutical, and medical device ���Biotech, pharmaceutical, and medical device companies have come to know Toxikon as a trusting partner. It is rewarding to be qualified as a CRO leader in quality, reliability, and innovation categories. This award validates our commitment to the life science companies by providing expertise and service they can depend on from product development through the regulatory process for timely market delivery.��� ��� Dr. Laxman S. Desai, president and CEO WIL Research ��� Ashland, OH www.wilresearch.com ��� (419) 289-8700 key locations: Ashland, OH; Hillsborough, NC; Skokie, IL; & ���s-Hertogenbosch, The Netherlands info@wilresearch.com Drug Life Cycle Stages: Research & Development ��� Discovery, Preclinical Main Service Areas: Bioanalytical, Preclinical SERVICES & CAPABILITIES: Toxicology ��� general toxicology, developmental and reproductive toxicology, inhalation toxicology, neurotoxicology, genetic toxicology, juvenile toxicology and ecotoxicology; Pharmacology ��� core battery, radiotelemetry, and RIP/JET; Chemistry ��� analytical and bioanalytical chemistry, ADME, immunochemistry, and physical chemical characterization; Pathology ��� immunohistochemistry and stereology; Regulatory ��� agrochemicals and biocides, program and regulatory services, and environmental risk assessment ���WIL Research is honored to be recognized as a quality leader in CRO industry. This data-driven award is a testament to our scientists��� and staff���s dedication, experience, and ability to truly listen to customers��� needs. We are committed to open communication and direct interaction with our customers, which gives us the ability to deliver meaningful results time and again. We pride ourselves on providing the highest quality of service while taking advantage of our breadth of global resources.��� ��� Dave Spaight, chairman and CEO 30 The CRO Leadership Awards 2013